Driving Pressure Limited Ventilation During Video-assisted Thoracoscopic Lobectomy

A Randomized Controlled Trial to Assess the Feasiblity of a Driving Pressure Limited Ventilation vs.Standard Strategy During Video-assisted Thoracoscopic Lobectomy

This study aims to investigate the feasibility of a driving pressure limited mechanical ventilation strategy compared to a conventional strategy in patients undergoing one-lung ventilation during Video-assisted thoracoscopic lobectomy.

Study Overview

Detailed Description

• More recently, the so-called lung-protective intraoperative ventilation strategies have been advocated to prevent lung injury. Such strategies aim at minimizing lung hyperinflation as well as cycling collapse and reopening of lung units, through the use of low tidal volumes (VTs) and positive end-expiratory pressure (PEEP). However, despite huge improvements in surgical and anesthesia techniques and management. It is surprising that, so far, mortality and pulmonary complication rates were not reduced over time .Recently, several investigations suggest an association between high driving pressure (the difference between the plateau pressure and the level of PEEP) and outcome for patients with acute respiratory distress syndrome. It is uncertain whether a similar association exists for high driving pressure during surgery and the occurrence of postoperative pulmonary complications. In this issue, Ary S Neto and colleagues report an individual patient data meta-analysis further investigating the risk of mechanical ventilation in healthy individuals during general anesthesia .After both a multivariate and mediation analysis, the driving pressure, but not the tidal volume or the positive end-expiratory pressure applied, seemed to be the only parameter that was associated with the development of postoperative pulmonary complications. This randomized controlled trial is aims to prove that driving pressure limited ventilation is superior in preventing postoperative pulmonary complications to existing protective ventilation.

Study Type

Interventional

Enrollment (Anticipated)

90

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Jiangsu
      • Xuzhou, Jiangsu, China, 221000
        • Recruiting
        • The Affiliated Hospital of Xuzhou Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Adults greater than or equal to 18 years
  2. ARISCAT(Assess Respiratory Risk in Surgical Patients in Catalonia)≥26 points
  3. Patients undergoing video-assisted thoracoscopic lobectomy

Exclusion Criteria:

  1. The American Society of Anesthesiologists (ASA) Physical Status classification greater than or equal to 4
  2. Emergency surgery
  3. Pulmonary hypertension
  4. Forced vital capacity or forced expiratory volume in 1 sec < 70% of the predicted values
  5. Coagulation disorder
  6. Pulmonary or extrapulmonary infections
  7. History of treatment with steroid in 3 months before surgery
  8. History of recurrent pneumothorax
  9. History of lung resection surgery
  10. History of mechanical ventilation in 2 weeks
  11. Body Mass Index[≥35 kg/m2 ]
  12. Patient who is contraindicated with application of positive end expiratory pressure

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Protective Ventilation 1
Intraoperatively ventilated patients with a tidal volume (VT) of 10 ml/kg of ideal body weight, the level of PEEP at 0 cmH2O and a FiO2 of100%.
Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
Active Comparator: Protective Ventilation 2
Intraoperatively ventilated patients with a tidal volume (VT) of 6 ml/kg of ideal body weight, the level of PEEP at 5cmH2O and a FiO2 of 60% with lung recruitment maneuvers.
Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
Experimental: Driving Pressure Limited Ventilation
The intervention arm receives driving pressure limited ventilation during one-lung ventilation
Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The incidence of postoperative pulmonary complications
Time Frame: within the first 3 days after surgery
Patient is regarded to have postoperative pulmonary complication when 4 or more positive variables exists according to Melbourne Group Scale.
within the first 3 days after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Partial pressure of oxygen in arterial blood
Time Frame: 15 min after induction, 20 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation, 1 hour after the end of surgery
15 min after induction, 20 and 60 min after start of one-lung ventilation, 15 min after restart of two-lung ventilation, 1 hour after the end of surgery
respiratory compliance
Time Frame: during surgery
Dynamic compliance, Static compliance
during surgery
TNF-α
Time Frame: the start of one-lung ventilation, 1 hour of one-lung ventilation and the end of one-lung ventilation
the start of one-lung ventilation, 1 hour of one-lung ventilation and the end of one-lung ventilation
IL-8
Time Frame: the start of one-lung ventilation, 1 hour of one-lung ventilation and the end of one-lung ventilation
the start of one-lung ventilation, 1 hour of one-lung ventilation and the end of one-lung ventilation
ICU mortality
Time Frame: Patients will be followed during the period of hospital stay, an expected average of 28 days
Patients will be followed during the period of hospital stay, an expected average of 28 days
In-hospital mortality
Time Frame: Patients will be followed during the period of hospital stay, an expected average of 28 days
Patients will be followed during the period of hospital stay, an expected average of 28 days
28-day survival
Time Frame: From day 0 to day 28
From day 0 to day 28

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2017

Primary Completion (Anticipated)

June 10, 2018

Study Completion (Anticipated)

June 10, 2018

Study Registration Dates

First Submitted

June 4, 2017

First Submitted That Met QC Criteria

June 5, 2017

First Posted (Actual)

June 6, 2017

Study Record Updates

Last Update Posted (Actual)

June 6, 2017

Last Update Submitted That Met QC Criteria

June 5, 2017

Last Verified

June 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • XYFY-2017-033

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Thoracic Surgery

Clinical Trials on Protective ventilation 1

Subscribe